- Home
- NAGE
as 09-18-2025 10:19am EST
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 766.4M | IPO Year: | N/A |
| Target Price: | $17.00 | AVG Volume (30 days): | 791.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.18 - $14.69 | Next Earning Date: | 10-30-2025 |
| Revenue: | $116,303,000 | Revenue Growth: | 35.90% |
| Revenue Growth (this year): | 29.05% | Revenue Growth (next year): | 21.09% |
Latest Niagen Bioscience Inc. Common Stock News
NAGE Breaking Stock News: Dive into NAGE Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Three Growth Stocks With Strong Insider Commitment
Simply Wall St.
3 months ago
Even though Niagen Bioscience (NASDAQ:NAGE) has lost US$55m market cap in last 7 days, shareholders are still up 623% over 3 years
Business Wire
3 months ago
Niagen Bioscience to Participate at the Roth 15th Annual London Conference
Business Wire
3 months ago
Niagen Bioscience to Participate in the BIO 2025 International Convention
Business Wire
3 months ago
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
Business Wire
3 months ago
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference
Simply Wall St.
4 months ago
3 Growth Companies With High Insider Ownership And Up To 18% Revenue Growth
Simply Wall St.
4 months ago
3 Stocks That May Be Trading Below Their Estimated Value
Compare NAGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAGE Niagen Bioscience Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.